Secondary analysis of the phase III NRG/RTOG 1016 trial in p16+ oropharyngeal cancer (375 analysed): quality of life change at 6 months did not differ between accelerated radiotherapy with cetuximab versus cisplatin on any domain.
Secondary analysisn = 375
Ringash et al. Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial